cardiff oncology | Cardiff Oncology

Keyword	CPC	PCC	Volume	Score	Length of keyword
cardiff oncology	1.36	0.3	4198	7	16
cardiff	0.21	1	1157	87	7
oncology	0.36	0.8	4173	24	8

Keyword	CPC	PCC	Volume	Score
cardiff oncology	1.32	0.9	2048	90
cardiff oncology stock	0.68	1	2360	28
cardiff oncology news	1.63	0.1	9747	81
cardiff oncology stock price	0.69	0.7	7963	62
cardiff oncology ariva	0.32	1	619	55
cardiff oncology buyout	0.31	0.2	3627	2
cardiff oncology funding	0.63	0.1	9509	20
cardiff oncology price target	1.9	0.7	7681	12
cardiff oncology pipeline	1.92	0.7	2374	74
cardiff oncology yahoo finance	1.42	0.8	6361	81
cardiff oncology aktie	1.56	0.3	8908	34
cardiff oncology discussion	1.68	0.9	896	61
cardiff oncology investor relations	0.2	0.6	2140	35
cardiff oncology inc	0.32	0.2	9911	73
pfizer cardiff oncology	1.83	0.7	2148	77
cardiff university radiotherapy and oncology	1.99	0.2	8759	34

Search Results related to cardiff oncology on Search Engine

Cardiff Oncology - Cardiff Oncology
cardiffoncology.com

https://cardiffoncology.com/

WEBCardiff Oncology is a clinical stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers.

DA: 39 PA: 18 MOZ Rank: 98

Onvansertib - Cardiff Oncology
cardiffoncology.com

https://cardiffoncology.com/onvansertib/

WEBOnvansertib - Cardiff Oncology. Onvansertib effectively targets PLK1. PLK1 is an enzyme over-expressed in many cancer types. It’s been known for decades to to be hijacked by tumor cells allowing uncontrolled growth in the M phase of the cell cycle. We now know PLK1 is involved in the repair of damaged DNA in the S phase of the cell cycle.

DA: 40 PA: 51 MOZ Rank: 96

Cardiff Oncology Announces Positive Clinical Data in Pancreatic …
yahoo.com

https://finance.yahoo.com/news/cardiff-oncology-announces-positive-clinical-200500411.html

WEBSAN DIEGO, Sept. 26, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...

DA: 34 PA: 19 MOZ Rank: 77

Investor Relations - Cardiff Oncology, Inc.
cardiffoncology.com

https://investors.cardiffoncology.com/

WEBCorporate Profile. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor that we are evaluating in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as KRAS ...

DA: 42 PA: 55 MOZ Rank: 6

ONSEMBLE mCRC - Cardiff Oncology
cardiffoncology.com

https://cardiffoncology.com/onsemble-mcrc/

WEBONSEMBLE mCRC - Cardiff Oncology. Clinical Programs. 1st line mCRC. 2nd line mCRC. mPDAC. The CRDF-004 phase 2 randomized trial for the 1st line treatment of patients with a RAS-mutated metastatic colorectal cancer (mCRC) is designed to generate preliminary safety and efficacy data, and confirm the optimal dose. ENDPOINTS. Primary.

DA: 85 PA: 56 MOZ Rank: 27

Cardiff Oncology Presents Novel Preclinical Data at AACR …
cardiffoncology.com

https://investors.cardiffoncology.com/news-releases/news-release-details/cardiff-oncology-presents-novel-preclinical-data-aacr-annual

WEBSAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the presentation of five abstracts at the American Association for Cancer Research (AACR), taking place from April 5-10, …

DA: 71 PA: 1 MOZ Rank: 17

Cardiff Oncology Provides Clinical Update on Phase 2 …
cardiffoncology.com

https://investors.cardiffoncology.com/news-releases/news-release-details/cardiff-oncology-provides-clinical-update-phase-2-randomized

WEBSAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today provided a clinical update on the first release of data from its second-line RAS-mutated metastatic colorectal cancer (mCRC) …

DA: 77 PA: 51 MOZ Rank: 10

Cardiff Oncology | LinkedIn
linkedin.com

https://www.linkedin.com/company/cardiffoncology

WEBAbout us. Cardiff Oncology is a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel...

DA: 87 PA: 65 MOZ Rank: 98

Cardiff Oncology Announces New Lead Program in First-Line …
cardiffoncology.com

https://cardiffoncology.com/wp-content/uploads/2023/08/08072023-Cardiff-Oncology-Press-Release-FINAL.pdf

WEBSAN DIEGO, August 7, 2023. Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced plans to advance the company’s lead program to the first-line setting of metastatic colorectal cancer ...

DA: 48 PA: 14 MOZ Rank: 27

Press Releases - Cardiff Oncology, Inc.
cardiffoncology.com

https://investors.cardiffoncology.com/news-events/press-releases

WEBSAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor. February 26, 2024. Read More.

DA: 39 PA: 55 MOZ Rank: 5